CA2491313C - Non-polymeric lipophilic pharmaceutical implant compositions for intraocular use - Google Patents
Non-polymeric lipophilic pharmaceutical implant compositions for intraocular use Download PDFInfo
- Publication number
- CA2491313C CA2491313C CA2491313A CA2491313A CA2491313C CA 2491313 C CA2491313 C CA 2491313C CA 2491313 A CA2491313 A CA 2491313A CA 2491313 A CA2491313 A CA 2491313A CA 2491313 C CA2491313 C CA 2491313C
- Authority
- CA
- Canada
- Prior art keywords
- composition
- glyceryl
- coo
- intraocular implant
- independently
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts, ocular implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7007—Drug-containing films, membranes or sheets
Abstract
Solid or semi-solid intraocular implant compositions are disclosed. The compositions contain a lipophilic compound but lack a polymeric ingredient.
Description
NON-POLYMERIC LIPOPHILIC PHARMACEUTICAL IMPLANT
COMPOSITIONS FOR INTRAOCULAR USE
BACKGROUND OF THE INVENTION
This invention relates to pharmaceutical implant compositions. In particular, this invention relates to the use of low molecular weight, lipophilic compounds in implant compositions for intraocular use.
Various solid and semi-solid drug delivery implants are known, including both non-erodible, non-degradable implants, such as those made using ethylene vinyl acetate, and erodible or biodegradable implants, such as those made using polyanhydrides or polylactides. Drug delivery implants, particularly ophthalmic ,5 drug delivery implants are generally characterized by at least one polymeric ingredient. In many instances, drug delivery implants contain more than one polymeric ingredient.
For example, U.S. Patent No. 5,773,019 discloses implantable controlled release devices for delivering drugs to the eye wherein the implantable device has an inner core containing an effective amount of a low solubility drug covered by a non-bioerodible polymer coating layer that is permeable to the low solubility drug.
U.S. Patent No. 5,378,475 discloses sustained release drug delivery devices that have an inner core or reservoir comprising a drug, a first coating layer which is essentially impermeable to the passage of the drug, and a second coating layer which is permeable to the drug. The first coating layer covers at least a portion of the inner core but at least a small portion of the inner core is not coated with the first coating layer. The second coating layer essentially completely covers the first coating layer and the uncoated portion of the inner core.
U.S. Patent No. 4,853,224 discloses biodegradable ocular implants comprising microencapsulated drugs for implantation into the anterior and/or posterior chambers of the eye. The polymeric encapsulating agent or lipid encapsulating agent is the primary element of the capsule. Many types of polymers are disclosed, but no implants that lack a biodegradable polymer are disclosed.
U.S. Patent No. 5,164,188 discloses the use of biodegradable implants in the suprachoroid of an eye. The implants are generally encapsulated. The capsule, for the most part, is a polymeric encapsulating agent. Material capable of being placed in a given area of the suprachoroid without migration, "such as oxycel, gelatin, silicone, etc." can also be used.
U.S. Patent No. 6,120,789 discloses the use of a non-polymeric composition for in situ formation of a solid matrix in an animal, and use of the composition as a medical device or as a sustained release delivery system for a biologically-active agent, among other uses. The composition is composed of a biocompatible, non-polymeric material and a pharmaceutically acceptable, organic solvent. The non-polymeric composition is biodegradable and/or bioerodible, and substantially insoluble in aqueous or body fluids. The organic solvent solubilizes the non-polymeric material, and has a solubility in water or other aqueous media ranging from miscible to dispersible. When placed into an implant site in an animal, the non-polymeric composition eventually transforms into a solid structure. The implant can be used for treating a tissue defect by enhancing cell growth and tissue regeneration, wound and organ repair, nerve regeneration, soft and hard tissue regeneration, and the like.
The composition can include a biologically-active agent (bioactive agent), as for example, an anti-inflammatory agent, an antiviral agent, antibacterial or antifungal agent useful for treating and preventing infections in the implant site, a growth factor, a hormone, and the like. The resulting implant provides a system for delivering the biologically-active agent to the animal. According to the `789 patent, suitable organic solvents are those that are biocompatible, pharmaceutically acceptable, and will at least partially dissolve the non-polymeric material. The organic solvent has a solubility in water ranging from miscible to dispersible. The solvent is capable of diffusing, dispersing, or leaching from the composition in situ into aqueous tissue fluid of the implant site such as blood serum, lymph, cerebral spinal fluid (CSF), saliva, and the like. According to the `789 patent, the solvent preferably has a Hildebrand (HLB) solubility ratio of from about 9-13 (cal/cm3)"2 and it is preferred that the degree of polarity of the solvent is effective to provide at least about 5%
solubility in water.
Polymeric ingredients in erodible or biodegradable implants must erode or degrade in order to be transported through ocular tissues and eliminated. Low molecular weight molecules, on the order of 4000 or less, can be transported through ocular tissues and eliminated without the need for biodegradation or erosion.
SUMMARY OF THE INVENTION
The present invention provides intraocular implant compositions comprising one or more low molecular weight, lipophilic compounds and a pharmaceutical drug, but lacking a polymeric ingredient and an organic solvent that is miscible with or dispersible in water. The compositions are solid or semi-solid at temperatures s37 C, average human eye temperature. The implants can be placed anywhere in the eye, including the conjunctival cul-de-sac, but are especially suitable for implantation inside of the eye.
COMPOSITIONS FOR INTRAOCULAR USE
BACKGROUND OF THE INVENTION
This invention relates to pharmaceutical implant compositions. In particular, this invention relates to the use of low molecular weight, lipophilic compounds in implant compositions for intraocular use.
Various solid and semi-solid drug delivery implants are known, including both non-erodible, non-degradable implants, such as those made using ethylene vinyl acetate, and erodible or biodegradable implants, such as those made using polyanhydrides or polylactides. Drug delivery implants, particularly ophthalmic ,5 drug delivery implants are generally characterized by at least one polymeric ingredient. In many instances, drug delivery implants contain more than one polymeric ingredient.
For example, U.S. Patent No. 5,773,019 discloses implantable controlled release devices for delivering drugs to the eye wherein the implantable device has an inner core containing an effective amount of a low solubility drug covered by a non-bioerodible polymer coating layer that is permeable to the low solubility drug.
U.S. Patent No. 5,378,475 discloses sustained release drug delivery devices that have an inner core or reservoir comprising a drug, a first coating layer which is essentially impermeable to the passage of the drug, and a second coating layer which is permeable to the drug. The first coating layer covers at least a portion of the inner core but at least a small portion of the inner core is not coated with the first coating layer. The second coating layer essentially completely covers the first coating layer and the uncoated portion of the inner core.
U.S. Patent No. 4,853,224 discloses biodegradable ocular implants comprising microencapsulated drugs for implantation into the anterior and/or posterior chambers of the eye. The polymeric encapsulating agent or lipid encapsulating agent is the primary element of the capsule. Many types of polymers are disclosed, but no implants that lack a biodegradable polymer are disclosed.
U.S. Patent No. 5,164,188 discloses the use of biodegradable implants in the suprachoroid of an eye. The implants are generally encapsulated. The capsule, for the most part, is a polymeric encapsulating agent. Material capable of being placed in a given area of the suprachoroid without migration, "such as oxycel, gelatin, silicone, etc." can also be used.
U.S. Patent No. 6,120,789 discloses the use of a non-polymeric composition for in situ formation of a solid matrix in an animal, and use of the composition as a medical device or as a sustained release delivery system for a biologically-active agent, among other uses. The composition is composed of a biocompatible, non-polymeric material and a pharmaceutically acceptable, organic solvent. The non-polymeric composition is biodegradable and/or bioerodible, and substantially insoluble in aqueous or body fluids. The organic solvent solubilizes the non-polymeric material, and has a solubility in water or other aqueous media ranging from miscible to dispersible. When placed into an implant site in an animal, the non-polymeric composition eventually transforms into a solid structure. The implant can be used for treating a tissue defect by enhancing cell growth and tissue regeneration, wound and organ repair, nerve regeneration, soft and hard tissue regeneration, and the like.
The composition can include a biologically-active agent (bioactive agent), as for example, an anti-inflammatory agent, an antiviral agent, antibacterial or antifungal agent useful for treating and preventing infections in the implant site, a growth factor, a hormone, and the like. The resulting implant provides a system for delivering the biologically-active agent to the animal. According to the `789 patent, suitable organic solvents are those that are biocompatible, pharmaceutically acceptable, and will at least partially dissolve the non-polymeric material. The organic solvent has a solubility in water ranging from miscible to dispersible. The solvent is capable of diffusing, dispersing, or leaching from the composition in situ into aqueous tissue fluid of the implant site such as blood serum, lymph, cerebral spinal fluid (CSF), saliva, and the like. According to the `789 patent, the solvent preferably has a Hildebrand (HLB) solubility ratio of from about 9-13 (cal/cm3)"2 and it is preferred that the degree of polarity of the solvent is effective to provide at least about 5%
solubility in water.
Polymeric ingredients in erodible or biodegradable implants must erode or degrade in order to be transported through ocular tissues and eliminated. Low molecular weight molecules, on the order of 4000 or less, can be transported through ocular tissues and eliminated without the need for biodegradation or erosion.
SUMMARY OF THE INVENTION
The present invention provides intraocular implant compositions comprising one or more low molecular weight, lipophilic compounds and a pharmaceutical drug, but lacking a polymeric ingredient and an organic solvent that is miscible with or dispersible in water. The compositions are solid or semi-solid at temperatures s37 C, average human eye temperature. The implants can be placed anywhere in the eye, including the conjunctival cul-de-sac, but are especially suitable for implantation inside of the eye.
According to one aspect of the present invention, there is provided an intraocular implant composition suitable for implanting in a site selected from the group consisting of the punctum, lacrimal canaliculus, anterior segment, posterior segment, sub-Tenon's space, suprachoroidal space, and subconjunctival space comprising a lipophilic compound having a molecular weight of 150 - 4000 and a pharmaceutically effective amount of a drug, but lacking a polymeric ingredient and an organic solvent that is miscible with or dispersible in water, wherein the composition is solid or semi-solid at temperatures <_ 37 C and the lipophilic compound is of the formula H2 Il R (I) wherein R1 is -H, -OH, -000H, -CnH2n+1-2m, -COOCnH2n+1-2m, -COO(CH2CH2O)nCH2CH2OH, -CH2R3, or R2, R3 and R4 are independently -H, -OH, -000H, -CnH2n+1-2m, -OOCCnH2n+1-2m, -COOCnH2n+1-2m, -COO(CH2CH2O)nCH2CH2OH, -CnH2n+1-2m000(CH2CH2O)nCH2CH2OH, -OOCCnH2n+i-2m000Cn'H2n'+1-2m', -COO-Na+, -COO-K+, -SO3H, -S03 Na+, - SO3 -K+, -NH2, -Cl, -N-Cn'H2n'+1 i CnH2n+1 or Cn"H2n"+l -N Cn'H2n'+1 I Cl-CnH2n+1 n, n' and n" are independently 0 - 50; and m and m' are independently 0 - 10, wherein the composition comprises at least 30% (wt.) of the lipophilic compound of formula (I).
3a According to another aspect of the present invention, there is provided a use of an intraocular implant composition for treating an ophthalmic disease or disorder, comprising the steps of the intraocular implant composition comprising a lipophilic compound having a molecular weight of 150 - 4000 and a pharmaceutically effective amount of an ophthalmically acceptable drug, but lacking a polymeric ingredient and an organic solvent that is miscible with or dispersible in water, wherein the composition is solid or semi-solid at temperatures <_ 37 C and the lipophilic compound is of the formula R (I) wherein R1 is -H, -OH, -COON, -CnH2n+1-2m, -COOCnH2n+1-2m, -COO(CH2CH2O)nCH2CH2OH, -CH2R3, or R2, R3 and R4 are independently -H, -OH, -000H, -CnH2n+1-2m, -OOCCnH2n+1-2m, -COOCnH2n+1-2m, -COO(CH2CH2O)nCH2CH2OH, -CnH2n+1-2m000(CH2CH2O)nCH2CH2OH, -OOCCnH2n+i-2m000Cn-Hen'+1-2m', -COO-Na+, -COOK+, -SO3H, -SO3-Na+, - SO3-K+, -NH2, -Cl, -N-Cn,H2n'+1 CnH2n+1 , or Cn"H2n"+ I
-N Cn'H2n'+l I Cl-CnH2n+l n, n' and n" are independently 0 - 50; and m and m' are independently 0 - 10, wherein the composition comprises at least 30% (wt.) of the lipophilic compound of formula (I).
3b BRIEF DESCRIPTION OF THE DRAWINGS
Fig. 1 shows the release of dexamethasone from implant compositions containing the indicated monoglyceride blends.
Fig. 2 shows the release of dexamethasone from implant compositions containing the indicated monoglycerides.
3c Fig. 3 shows the release of dexamethasone from implant compositions containing glyceryl monostearate and a varying amount of surfactant.
DETAILED DESCRIPTION OF THE INVENTION
Unless indicated otherwise, all ingredient amounts expressed in percentage terms are presented as % w/w.
As used herein, "implant" means a solid or semi-solid mass that contains one or more drugs and includes, but is not limited to, beads, pellets, rods, films and microparticles. Microparticles can be suspended in aqueous or nonaqueous liquid carriers.
The implant compositions of the present invention, which lack both a polymeric ingredient and an organic solvent that is miscible with or dispersible in water, comprise a pharmaceutical drug and one or more lipophilic compounds having a molecular weight of 150 - 4000, wherein the lipophilic compounds are of the formula:
(I) wherein R1 is -H, -OH, -000H, -CnH2n+1.2m, -COOCnH2n+1_2m, -COO(CH2CH2O)nCH2CH2OH, -CH2R3, or I
R2, R3 and R4 are independently -H, -OH, -COON, -CnH2n+1-2m, -OOCCnH2n+1-2m, -COOCnH2n+1_2m, -COO(CH2CH2O)nCH2CH2OH, -CnH2n+,-2m000(CH2CH2O)nCH2CH2OH, OOCCnH2n+i_2m000Cn'H2n'+1.2m-, -COO" Na+, -COO- K+, -SO3H, -S03 Na+, - S03 K+, -NH2, -Cl, - i - Cn=H2n'+, CnH2n+, , or Cn.H2n.+, - i -Cn.H2 .+, Cl CnH2n+1 n, n' and n" are independently 0 - 50; and m and m' are independently 0 - 10.
Preferably, the molecular weight of the lipophilic compounds used in the present invention is <2000, and most preferably <_ 1000. If the implant of the present invention contains only one lipophilic compound of formula (I), then the lipophilic compound must have a melting point >_ 34 C, preferably 2:37 C. If the implant contains two or more lipophilic compounds of formula (I), it is only necessary that the mixture has a melting point >_ 34 C, and preferably ? 37 C.
The lipophilic compounds are water-insoluble at 37 C (i.e., have a solubility in water of < 0.5 mg/mi at 37 C).
Preferred are the lipophilic compounds of formula (I) wherein R' is, -CnH2n+1_2m, -COOCnH2n+1-2m, -COO(CH2CH2O)nCH2CH2OH, -CH2R3, or I
R2, R3 and R4 are independently -H, -OH, -COOH, -C,,H2n+1-2m, OOCCnH2n+1_2m, -COOCnH2n+1-2m, -COO(CH2CH2O)nCH2CH2OH, -CnH2n+1-2m000(CH2CH2O)nCH2CH2OH, or -OOCCnH2n+1-2m000Cn'H2n'+1-2m';
n, n' and n" are independently 0 - 401, and m and m' are independently 0 - 5.
Most preferred are the lipophilic compounds of formula (I) wherein R1 is R2, R3 and R4 are independently -H, -OH, -COOH, -CnH2<,+1-2m, or -OOCCnH2n+1.2m;
n, n' and n" are independently 0 - 30; and m and m' are independently 0 - 3.
Especially preferred lipophilic compounds of formula (I) are glyceryl monolaurate; glyceryl dilaurate; glyceryl monomyristate; glyceryl dimyristate;
glyceryl monopalmitate; glyceryl dipalmitate; glyceryl monostearate; glyceryl distearate; glyceryl monooleate; glyceryl dioleate; glyceryl monolinoleate;
glyceryl dilinoleate; glyceryl monoarachidate; glyceryl diarachidate; glyceryl monobehenate; and glyceryl dibehenate.
As used herein, "an organic solvent miscible with or dispersible in water"
means an organic solvent that is biocompatible, pharmaceutically acceptable, and has a solubility in water ranging from miscible to dispersible. These organic solvents that are excluded from the compositions of the present claims are the same as those that are essential in the compositions described in U.S.
Patent No. 6,120,789.
The lipophilic compounds of the present invention can be made by methods known in the art and many such compounds are commercially available. For example, commercial suppliers include NuChek Prep (Elysian, Minnesota),Quest International (Hoffman Estates, Illinois), which produces such compounds under the Myvaplex and Myvacet brands, and Gattefossa (Saint-Priest, France), which produces such compounds under the Gelucire and Geleol brands. Suitable lipophilic compounds include, but are not limited to, the following commercially available products.
diethylene glycol monostearate (Hydrine ; m.p. = 45.5 - 48.5 C);
propylene glycol mono- and diesters of stearic and palmitic acid (Monosteol ;
m.p. = 34.0 - 37.5 C; 'propylene glycol monostearate');
glyceryl monostearate (Geleol ; m.p. = 70 C);
glyceryl monolinoleate (Maisine 35-1; m.p. = -6.5 C);
glyceryl monooleate (Peceol ; m.p. = 16 C);
the mixture of monoglycerides sold as Myverol 18-85 (m.p. = 46 C);
the mixture of glyceryl monostearate (85 - 90%) and glyceryl monopalmitate (10 - 15%) (Myvaple) 600P; m.p. = 69 C);
glyceryl esters of saturated C12 - C18 saturated fatty acid esters (Gelucire 43/01;
m.p. = 42 - 46 C);
glyceryl esters of saturated C8- C18 saturated fatty acid esters (Gelucire 33/01;
m.p. = 33 - 37 C); and glyceryl esters of saturated C12- C18 saturated fatty acid esters (Gelucire 39/01;
m.p. = 37.5 - 41 C); and The implant compositions of the present invention comprise one or more lipophilic compounds of formula (I) in a total concentration of at least 10%, preferably at least 30%, and most preferably at least 50%.
3a According to another aspect of the present invention, there is provided a use of an intraocular implant composition for treating an ophthalmic disease or disorder, comprising the steps of the intraocular implant composition comprising a lipophilic compound having a molecular weight of 150 - 4000 and a pharmaceutically effective amount of an ophthalmically acceptable drug, but lacking a polymeric ingredient and an organic solvent that is miscible with or dispersible in water, wherein the composition is solid or semi-solid at temperatures <_ 37 C and the lipophilic compound is of the formula R (I) wherein R1 is -H, -OH, -COON, -CnH2n+1-2m, -COOCnH2n+1-2m, -COO(CH2CH2O)nCH2CH2OH, -CH2R3, or R2, R3 and R4 are independently -H, -OH, -000H, -CnH2n+1-2m, -OOCCnH2n+1-2m, -COOCnH2n+1-2m, -COO(CH2CH2O)nCH2CH2OH, -CnH2n+1-2m000(CH2CH2O)nCH2CH2OH, -OOCCnH2n+i-2m000Cn-Hen'+1-2m', -COO-Na+, -COOK+, -SO3H, -SO3-Na+, - SO3-K+, -NH2, -Cl, -N-Cn,H2n'+1 CnH2n+1 , or Cn"H2n"+ I
-N Cn'H2n'+l I Cl-CnH2n+l n, n' and n" are independently 0 - 50; and m and m' are independently 0 - 10, wherein the composition comprises at least 30% (wt.) of the lipophilic compound of formula (I).
3b BRIEF DESCRIPTION OF THE DRAWINGS
Fig. 1 shows the release of dexamethasone from implant compositions containing the indicated monoglyceride blends.
Fig. 2 shows the release of dexamethasone from implant compositions containing the indicated monoglycerides.
3c Fig. 3 shows the release of dexamethasone from implant compositions containing glyceryl monostearate and a varying amount of surfactant.
DETAILED DESCRIPTION OF THE INVENTION
Unless indicated otherwise, all ingredient amounts expressed in percentage terms are presented as % w/w.
As used herein, "implant" means a solid or semi-solid mass that contains one or more drugs and includes, but is not limited to, beads, pellets, rods, films and microparticles. Microparticles can be suspended in aqueous or nonaqueous liquid carriers.
The implant compositions of the present invention, which lack both a polymeric ingredient and an organic solvent that is miscible with or dispersible in water, comprise a pharmaceutical drug and one or more lipophilic compounds having a molecular weight of 150 - 4000, wherein the lipophilic compounds are of the formula:
(I) wherein R1 is -H, -OH, -000H, -CnH2n+1.2m, -COOCnH2n+1_2m, -COO(CH2CH2O)nCH2CH2OH, -CH2R3, or I
R2, R3 and R4 are independently -H, -OH, -COON, -CnH2n+1-2m, -OOCCnH2n+1-2m, -COOCnH2n+1_2m, -COO(CH2CH2O)nCH2CH2OH, -CnH2n+,-2m000(CH2CH2O)nCH2CH2OH, OOCCnH2n+i_2m000Cn'H2n'+1.2m-, -COO" Na+, -COO- K+, -SO3H, -S03 Na+, - S03 K+, -NH2, -Cl, - i - Cn=H2n'+, CnH2n+, , or Cn.H2n.+, - i -Cn.H2 .+, Cl CnH2n+1 n, n' and n" are independently 0 - 50; and m and m' are independently 0 - 10.
Preferably, the molecular weight of the lipophilic compounds used in the present invention is <2000, and most preferably <_ 1000. If the implant of the present invention contains only one lipophilic compound of formula (I), then the lipophilic compound must have a melting point >_ 34 C, preferably 2:37 C. If the implant contains two or more lipophilic compounds of formula (I), it is only necessary that the mixture has a melting point >_ 34 C, and preferably ? 37 C.
The lipophilic compounds are water-insoluble at 37 C (i.e., have a solubility in water of < 0.5 mg/mi at 37 C).
Preferred are the lipophilic compounds of formula (I) wherein R' is, -CnH2n+1_2m, -COOCnH2n+1-2m, -COO(CH2CH2O)nCH2CH2OH, -CH2R3, or I
R2, R3 and R4 are independently -H, -OH, -COOH, -C,,H2n+1-2m, OOCCnH2n+1_2m, -COOCnH2n+1-2m, -COO(CH2CH2O)nCH2CH2OH, -CnH2n+1-2m000(CH2CH2O)nCH2CH2OH, or -OOCCnH2n+1-2m000Cn'H2n'+1-2m';
n, n' and n" are independently 0 - 401, and m and m' are independently 0 - 5.
Most preferred are the lipophilic compounds of formula (I) wherein R1 is R2, R3 and R4 are independently -H, -OH, -COOH, -CnH2<,+1-2m, or -OOCCnH2n+1.2m;
n, n' and n" are independently 0 - 30; and m and m' are independently 0 - 3.
Especially preferred lipophilic compounds of formula (I) are glyceryl monolaurate; glyceryl dilaurate; glyceryl monomyristate; glyceryl dimyristate;
glyceryl monopalmitate; glyceryl dipalmitate; glyceryl monostearate; glyceryl distearate; glyceryl monooleate; glyceryl dioleate; glyceryl monolinoleate;
glyceryl dilinoleate; glyceryl monoarachidate; glyceryl diarachidate; glyceryl monobehenate; and glyceryl dibehenate.
As used herein, "an organic solvent miscible with or dispersible in water"
means an organic solvent that is biocompatible, pharmaceutically acceptable, and has a solubility in water ranging from miscible to dispersible. These organic solvents that are excluded from the compositions of the present claims are the same as those that are essential in the compositions described in U.S.
Patent No. 6,120,789.
The lipophilic compounds of the present invention can be made by methods known in the art and many such compounds are commercially available. For example, commercial suppliers include NuChek Prep (Elysian, Minnesota),Quest International (Hoffman Estates, Illinois), which produces such compounds under the Myvaplex and Myvacet brands, and Gattefossa (Saint-Priest, France), which produces such compounds under the Gelucire and Geleol brands. Suitable lipophilic compounds include, but are not limited to, the following commercially available products.
diethylene glycol monostearate (Hydrine ; m.p. = 45.5 - 48.5 C);
propylene glycol mono- and diesters of stearic and palmitic acid (Monosteol ;
m.p. = 34.0 - 37.5 C; 'propylene glycol monostearate');
glyceryl monostearate (Geleol ; m.p. = 70 C);
glyceryl monolinoleate (Maisine 35-1; m.p. = -6.5 C);
glyceryl monooleate (Peceol ; m.p. = 16 C);
the mixture of monoglycerides sold as Myverol 18-85 (m.p. = 46 C);
the mixture of glyceryl monostearate (85 - 90%) and glyceryl monopalmitate (10 - 15%) (Myvaple) 600P; m.p. = 69 C);
glyceryl esters of saturated C12 - C18 saturated fatty acid esters (Gelucire 43/01;
m.p. = 42 - 46 C);
glyceryl esters of saturated C8- C18 saturated fatty acid esters (Gelucire 33/01;
m.p. = 33 - 37 C); and glyceryl esters of saturated C12- C18 saturated fatty acid esters (Gelucire 39/01;
m.p. = 37.5 - 41 C); and The implant compositions of the present invention comprise one or more lipophilic compounds of formula (I) in a total concentration of at least 10%, preferably at least 30%, and most preferably at least 50%.
The implant compositions of the present invention comprise a pharmaceutically effective amount of an ophthalmic drug. If necessary or desired, more than one drug can be included in the implant of the present invention. Many types of ophthalmic drugs are known, including but not limited to: anti-glaucoma agents, such as beta-blockers including timolol, betaxolol, levobetaxolol, carteolol, miotics including pilocarpine, carbonic anhydrase inhibitors, prostaglandin analogues, seretonergics, muscarinics, dopaminergic agonists, adrenergic agonists including apraclonidine and brimonidine; anti-infective agents including quinolones such as ciprofloxacin, and aminoglycosides such as tobramycin and gentamicin; non-steroidal and steroidal anti-inflammatory agents, such as suprofen, diclofenac, ketorolac, rimexolone, dexamethasone and tetrahydrocortisol; growth factors, such as VEGF;
immunosuppressant agents; neuroprotectant agents; angiogenesis-inhibiting agents and anti-allergy agents including olopatadine. The ophthalmic drug may be present in the form of a pharmaceutically acceptable salt, such as timolol maleate, brimonidine tartrate or sodium diclofenac. Compositions of the present invention may also include combinations of ophthalmic drugs, such as combinations of (i) a beta-blocker selected from the group consisting of betaxolol and timolol, and (ii) a prostaglandin selected from the group consisting of latanoprost; 15-keto latanoprost; fluprostenol isopropyl ester (especially 1R-[1 a(Z),2(3(1 E,3R*),3a,5a]-7-[3,5-d ihyd roxy-2-[3-hyd roxy-4-[3-(trifluoromethyl)-phenoxy]-1-butenyl]cyclo-pentyl-]-5-heptenoic acid, 1-methylethyl ester);
isopropyl [2R(1 E,3R),3S(4Z),4R]-7-[tetrahydro-2-[4-(3-chlorophenoxy)-3-hydroxy-1-butenyl]-4-hydroxy-3-furanyl]-4-heptenoate; and (5Z)-(9R,11 R,15R)-9-chloro-15-cyclohexyl-11,15-dihydroxy-3-oxa-16,17,18,19,20-pentanor-5-prostenoic acid isopropyl ester. The total amount of drug contained in the implant compositions of the present invention is preferably not greater than 50%.
In addition to the lipophilic compound of formula (I) and an ophthalmic drug, the implant compositions of the present invention optionally comprise one or more excipients. Many excipients for solid and semi-solid pharmaceutical compositions are known. Examples of suitable excipients include, but are not limited to: surfactants, preservatives, and stabilizers.
immunosuppressant agents; neuroprotectant agents; angiogenesis-inhibiting agents and anti-allergy agents including olopatadine. The ophthalmic drug may be present in the form of a pharmaceutically acceptable salt, such as timolol maleate, brimonidine tartrate or sodium diclofenac. Compositions of the present invention may also include combinations of ophthalmic drugs, such as combinations of (i) a beta-blocker selected from the group consisting of betaxolol and timolol, and (ii) a prostaglandin selected from the group consisting of latanoprost; 15-keto latanoprost; fluprostenol isopropyl ester (especially 1R-[1 a(Z),2(3(1 E,3R*),3a,5a]-7-[3,5-d ihyd roxy-2-[3-hyd roxy-4-[3-(trifluoromethyl)-phenoxy]-1-butenyl]cyclo-pentyl-]-5-heptenoic acid, 1-methylethyl ester);
isopropyl [2R(1 E,3R),3S(4Z),4R]-7-[tetrahydro-2-[4-(3-chlorophenoxy)-3-hydroxy-1-butenyl]-4-hydroxy-3-furanyl]-4-heptenoate; and (5Z)-(9R,11 R,15R)-9-chloro-15-cyclohexyl-11,15-dihydroxy-3-oxa-16,17,18,19,20-pentanor-5-prostenoic acid isopropyl ester. The total amount of drug contained in the implant compositions of the present invention is preferably not greater than 50%.
In addition to the lipophilic compound of formula (I) and an ophthalmic drug, the implant compositions of the present invention optionally comprise one or more excipients. Many excipients for solid and semi-solid pharmaceutical compositions are known. Examples of suitable excipients include, but are not limited to: surfactants, preservatives, and stabilizers.
Suitable surfactants include tyloxapol, polysorbate 20, polysorbate 60, and polysorbate 80 surfactants. A preferred surfactant is polysorbate 80.
Suitable preservatives include quaternary ammonium preservatives such as polyquaternium-1 and benzalkonium halides. Preferred benzalkonium halides are benzalkonium chloride ("BAC") and benzalkonium bromide.
Suitable stabilizers include chelating agents, such as edetate disodium, and antioxidants, such as ascorbic acid and citric acid.
The implant compositions may be fashioned into a shape suitable for implantation into the eye. For example, such shapes include, but are not limited to cylindrical, conical and spherical shapes. Alternatively, the implant compositions may be of a shape and size such that they may be suspended in a liquid carrier and injected or deposited into the eye. The size and shape of the implant of the present invention will depend on a number of factors, including the selected drug, the target disease and the selected implant location. The implants of the present invention may be implanted anywhere in the eye, including the conjunctival cul-de-sac, punctum and lacrimal canaliculus, anterior and posterior segments, and the sub-Tenon's, suprachoroidal and subconjunctival spaces.
Although the implant compositions are preferably administered as a solid or semi-solid, in one embodiment the composition is warmed and administered in a semi-solid or liquid state through a cannula. After cooling to body temperature at the site of administration, the composition will form a semi-solid or solid implant.
The following examples are intended to illustrate, but not limit, the present invention.
Suitable preservatives include quaternary ammonium preservatives such as polyquaternium-1 and benzalkonium halides. Preferred benzalkonium halides are benzalkonium chloride ("BAC") and benzalkonium bromide.
Suitable stabilizers include chelating agents, such as edetate disodium, and antioxidants, such as ascorbic acid and citric acid.
The implant compositions may be fashioned into a shape suitable for implantation into the eye. For example, such shapes include, but are not limited to cylindrical, conical and spherical shapes. Alternatively, the implant compositions may be of a shape and size such that they may be suspended in a liquid carrier and injected or deposited into the eye. The size and shape of the implant of the present invention will depend on a number of factors, including the selected drug, the target disease and the selected implant location. The implants of the present invention may be implanted anywhere in the eye, including the conjunctival cul-de-sac, punctum and lacrimal canaliculus, anterior and posterior segments, and the sub-Tenon's, suprachoroidal and subconjunctival spaces.
Although the implant compositions are preferably administered as a solid or semi-solid, in one embodiment the composition is warmed and administered in a semi-solid or liquid state through a cannula. After cooling to body temperature at the site of administration, the composition will form a semi-solid or solid implant.
The following examples are intended to illustrate, but not limit, the present invention.
Example 1: Placebo pellets 0.25 g of polysorbate 80 and 4.75 g of the monoglyceride Myverol 18-35 were added to a scintillation vial. The monoglyceride was melted by heating in a water bath. The polysorbate 80 and monoglyceride were then mixed by swirling.
Pellets were made by cooling the solution in a cylindrical mold. This procedure was repeated for the monoglycerides Myverol 18-50, Myverol 18-85, and Myaplex 600P.
In order to illustrate the relationship between the exemplified materials and formula (I), Myverol 18-35, Myverol 18-50 and Myverol 18-85 contain, according to their manufacturer, the following ingredients in the proportions shown:
a) Myverol 18-35 Monoglyceride Ingredient Abbreviation Wt.%
glyceryl monolaurate C12.0 0.3 glyceryl monomyristate C14.0 1.1 glyceryl monopalmitate C16.0 44.1 glyceryl monostearate C18.0 4.5 glyceryl monooleate C18.1 39.3 glyceryl monolinoleate C18.2 10.2 glyceryl monoarachidate C20.0 0.3 b) Myverol 18-50 Monoglyceride Ingredient Abbreviation Wt.%
glyceryl monomyristate C14.0 0.1 glyceryl monopalmitate C16.0 10.8 glyceryl monostearate C18.0 12.6 glyceryl monooleate C18.1 73.9 glyceryl monolinoleate C18.2 1.9 glyceryl monoarachidate C20.0 0.3 glyceryl monobehenate C22.0 0.3 c) Myverol 18-85 Mono-glyceride Ingredient Abbreviation Wt.%
glyceryl monomyristate C14.0 0.8 glyceryl monopalmitate C16.0 22.3 glyceryl monostearate C18.0 2.5 glyceryl monooleate C18.1 17.6 glyceryl monolinoleate C18.2 54.8 glyceryl monoarachidate C20.0 0.3 glyceryl monobehenate C22.0 0.3 C18.0 represents the compound:
I I
HC-OH
C18.1 represents the compound:
H2C-O-C-(CH2)7 -HC=CH-(CH2)7-CH3 HC-OH
C18.2 represents the compound:
H2C-O-C-(CH2)7 -HC=CH-C-HC=CH-(CH2)4-CH3 Example 2: Implant compositions containing dexamethasone 1 x 3 mm cylindrical pellets of the formulations shown in Table 1 below were prepared by combining the indicated ingredients in a scintillation vial, melting the lipophilic compound(s) of formula (I) by heating in a water bath, mixing by swirling, and then cooling the mixed, melted formulations in cylindrical molds.
Table 1: Formulations Formulatio Compound(s) of Dexamethasone Polysorbate 80 Figure #
n # Formula I wt.% wt.%
1 M a lex 600P 3.5 None 1 2 M erol18-85 3.5 None 1 3 Myvacet 5-07 3.5 1.5 1 4 M acet 7-07 3.5 1.5 1 5 Glyceryl 3.5 None 2 Monostearate 6 Glyceryl 3.5 None 2 Monomyristate 7 Glyceryl 3.5 None 2 Monobehenitate 8 Glyceryl 3.5 None 3 Monostearate 9 Glyceryl 3.5 1.5 3 Monostearate Glyceryl 3.5 2.5 3 Monostearate 11 Glyceryl 3.5 5 3 Monostearate The release of dexamethasone from each formulation shown in Table 1 was 10 measured by placing one pellet in a 2 ml vial containing 1.5 ml of phosphate buffered saline. Phosphate buffered saline ("PBS") contains 0.8% NaCl, 0.12%
Na2HPO4, and 0.06% NaH2PO4:H20. The vial is then placed in an oven at 37 C. At each time point, the vial is gently inverted twice, 60 NI of the PBS is removed from the vial for HPLC analysis of dexamethasone, 60 p1 of fresh PBS
is added to the vial, and the vial placed back into the oven until the next time point. Each formulation is run in triplicate. The results are shown in Figures 3.
Example 3: Implant compositions formulated as particles suspended in a liquid carrier.
A 75:20:5 mixture of anecortave acetate powder, glyceryl monostearate and polysorbate 80 is heated to melt the glyceryl monostearate and mixed. This mixture is then spray dried to produce particles. The particles are then suspended in an aqueous vehicle comprising sodium chloride, sodium dibasic phosphate, sodium monobasic phosphate, carboxymethyl cellulose and tyloxapol to produce a composition suitable for injection.
Example 4: Implant compositions warmed before administration and injected through a cannula.
A 50:45:5 mixture of anecortave acetate powder, Gelucire 39/01 (glycerol esters of saturated C12-C18 saturated fatty acid esters are heated to melt the Gelucire 39/01 and mixed. Before injection, this composition is heated to about 41 C
and is drawn in a syringe. It is then injected through a cannula in the sub-tenon's space. Upon cooling to 37 C, it forms a solid waxy mass.
Example 5: Implant composition containing 80 p.g of a prostaglandin.
Two 1 l-sized cylindrical pellets each containing 80 g of the prostaglandin analogue (5Z)-(9R,11 R,15R)-9-chloro-15-cyclohexyl-11,15-dihydroxy-3-oxa-16,17,18,19,20-pentanor-5-prostenoic acid isopropyl ester were prepared by combining the prostaglandin analogue with the necessary amount of the product Precirol ATO 5 (Gattefossa) in a scintillation vial, melting the lipophilic compounds by heating in a water bath, mixing by swirling, and then cooling the mixed, melted formulations in cylindrical molds. According to the manufacturer, Precirol ATO 5 is composed of mono-, di- and triglycerides of palmitostearic acid, with the diester fraction being predominant. Precirol ATO 5 is synthesized by esterification of glycerol by palmitostearic acid.
The release of the prostaglandin analogue from the pellets was measured as follows: after weighing, the pellets were placed in scintillation vials with 20 ml of PBS. The vials were stored in a 37 C oven. At each time point, the vial was gently inverted a few times (about 5 times), then 300 I of the dissolution sample was removed from the vial and the vial returned to the oven. The amount of prostaglandin analogue contained in the sample was determined by HPLC
analysis. The results are shown in Table 2.
Table 2 Time Cumulative Drug Release Cumulative Drug Release (days) ( g) (% of initial 80 g) 1 1.70 1.84 2.18 2.17 3 28.6 32 36.67 37.65 8 73 76.6 93.59 90.12 11* 65 69.4 83.33 81.65 * Drug may be degrading in the dissolution medium.
Example 6: Implant composition containing 200 pg of a prostaglandin.
Two 3 l-sized cylindrical pellets each containing 200 g of (5Z)-(9R,11 R,15R)-9-chloro-1 5-cyclohexyl-1 1,1 5-dihydroxy-3-oxa-16,17,18,19,20-pentanor-5-prostenoic acid isopropyl ester were prepared by combining the prostaglandin analogue with the necessary amount of the product Compritol 888 ATO
(Gattefossa) in a scintillation vial, melting the lipophilic compounds by heating in a water bath, mixing by swirling, and then cooling the mixed, melted formulations in cylindrical molds. According to the manufacturer, Compritol 888 ATO is composed of mono-, di- and triglycerides of behenic acid, with the diester fraction being predominant. Compritol 888 ATO is synthesized by esterification of glycerol by behenic acid.
The release of the prostaglandin analogue from the pellets was measured as follows: after weighing, the pellets were placed in scintillation vials with 20 ml of PBS. The vials were stored in a 37 C oven. At each time point, the vial was gently inverted a few times (about 5 times), then 300 l of the dissolution sample was removed from the vial and the vial returned to the oven. The amount of prostaglandin analogue contained in the sample was determined by HPLC
analysis. The results are shown in Table 3.
Table 3 Time Cumulative Drug Release Cumulative % Drug Release (days) ( g) (% of initial 80 g) 1 12.18 11.38 5.37 4.78 3 3.32 3.02 1.46 1.27 8 12.1 14.04 5.33 5.90 11 25.6 31 11.28 13.03 15 52.6 66.4 23.17 27.90 22 54.6 102.4 24.05 43.03 30 88.8 107.4 39.12 45.13 The invention has been described by reference to certain preferred embodiments; however, it should be understood that it may be embodied in other specific forms or variations thereof without departing from its spirit or essential characteristics. The embodiments described above are therefore considered to be illustrative in all respects and not restrictive, the scope of the invention being indicated by the appended claims rather than by the foregoing description.
Pellets were made by cooling the solution in a cylindrical mold. This procedure was repeated for the monoglycerides Myverol 18-50, Myverol 18-85, and Myaplex 600P.
In order to illustrate the relationship between the exemplified materials and formula (I), Myverol 18-35, Myverol 18-50 and Myverol 18-85 contain, according to their manufacturer, the following ingredients in the proportions shown:
a) Myverol 18-35 Monoglyceride Ingredient Abbreviation Wt.%
glyceryl monolaurate C12.0 0.3 glyceryl monomyristate C14.0 1.1 glyceryl monopalmitate C16.0 44.1 glyceryl monostearate C18.0 4.5 glyceryl monooleate C18.1 39.3 glyceryl monolinoleate C18.2 10.2 glyceryl monoarachidate C20.0 0.3 b) Myverol 18-50 Monoglyceride Ingredient Abbreviation Wt.%
glyceryl monomyristate C14.0 0.1 glyceryl monopalmitate C16.0 10.8 glyceryl monostearate C18.0 12.6 glyceryl monooleate C18.1 73.9 glyceryl monolinoleate C18.2 1.9 glyceryl monoarachidate C20.0 0.3 glyceryl monobehenate C22.0 0.3 c) Myverol 18-85 Mono-glyceride Ingredient Abbreviation Wt.%
glyceryl monomyristate C14.0 0.8 glyceryl monopalmitate C16.0 22.3 glyceryl monostearate C18.0 2.5 glyceryl monooleate C18.1 17.6 glyceryl monolinoleate C18.2 54.8 glyceryl monoarachidate C20.0 0.3 glyceryl monobehenate C22.0 0.3 C18.0 represents the compound:
I I
HC-OH
C18.1 represents the compound:
H2C-O-C-(CH2)7 -HC=CH-(CH2)7-CH3 HC-OH
C18.2 represents the compound:
H2C-O-C-(CH2)7 -HC=CH-C-HC=CH-(CH2)4-CH3 Example 2: Implant compositions containing dexamethasone 1 x 3 mm cylindrical pellets of the formulations shown in Table 1 below were prepared by combining the indicated ingredients in a scintillation vial, melting the lipophilic compound(s) of formula (I) by heating in a water bath, mixing by swirling, and then cooling the mixed, melted formulations in cylindrical molds.
Table 1: Formulations Formulatio Compound(s) of Dexamethasone Polysorbate 80 Figure #
n # Formula I wt.% wt.%
1 M a lex 600P 3.5 None 1 2 M erol18-85 3.5 None 1 3 Myvacet 5-07 3.5 1.5 1 4 M acet 7-07 3.5 1.5 1 5 Glyceryl 3.5 None 2 Monostearate 6 Glyceryl 3.5 None 2 Monomyristate 7 Glyceryl 3.5 None 2 Monobehenitate 8 Glyceryl 3.5 None 3 Monostearate 9 Glyceryl 3.5 1.5 3 Monostearate Glyceryl 3.5 2.5 3 Monostearate 11 Glyceryl 3.5 5 3 Monostearate The release of dexamethasone from each formulation shown in Table 1 was 10 measured by placing one pellet in a 2 ml vial containing 1.5 ml of phosphate buffered saline. Phosphate buffered saline ("PBS") contains 0.8% NaCl, 0.12%
Na2HPO4, and 0.06% NaH2PO4:H20. The vial is then placed in an oven at 37 C. At each time point, the vial is gently inverted twice, 60 NI of the PBS is removed from the vial for HPLC analysis of dexamethasone, 60 p1 of fresh PBS
is added to the vial, and the vial placed back into the oven until the next time point. Each formulation is run in triplicate. The results are shown in Figures 3.
Example 3: Implant compositions formulated as particles suspended in a liquid carrier.
A 75:20:5 mixture of anecortave acetate powder, glyceryl monostearate and polysorbate 80 is heated to melt the glyceryl monostearate and mixed. This mixture is then spray dried to produce particles. The particles are then suspended in an aqueous vehicle comprising sodium chloride, sodium dibasic phosphate, sodium monobasic phosphate, carboxymethyl cellulose and tyloxapol to produce a composition suitable for injection.
Example 4: Implant compositions warmed before administration and injected through a cannula.
A 50:45:5 mixture of anecortave acetate powder, Gelucire 39/01 (glycerol esters of saturated C12-C18 saturated fatty acid esters are heated to melt the Gelucire 39/01 and mixed. Before injection, this composition is heated to about 41 C
and is drawn in a syringe. It is then injected through a cannula in the sub-tenon's space. Upon cooling to 37 C, it forms a solid waxy mass.
Example 5: Implant composition containing 80 p.g of a prostaglandin.
Two 1 l-sized cylindrical pellets each containing 80 g of the prostaglandin analogue (5Z)-(9R,11 R,15R)-9-chloro-15-cyclohexyl-11,15-dihydroxy-3-oxa-16,17,18,19,20-pentanor-5-prostenoic acid isopropyl ester were prepared by combining the prostaglandin analogue with the necessary amount of the product Precirol ATO 5 (Gattefossa) in a scintillation vial, melting the lipophilic compounds by heating in a water bath, mixing by swirling, and then cooling the mixed, melted formulations in cylindrical molds. According to the manufacturer, Precirol ATO 5 is composed of mono-, di- and triglycerides of palmitostearic acid, with the diester fraction being predominant. Precirol ATO 5 is synthesized by esterification of glycerol by palmitostearic acid.
The release of the prostaglandin analogue from the pellets was measured as follows: after weighing, the pellets were placed in scintillation vials with 20 ml of PBS. The vials were stored in a 37 C oven. At each time point, the vial was gently inverted a few times (about 5 times), then 300 I of the dissolution sample was removed from the vial and the vial returned to the oven. The amount of prostaglandin analogue contained in the sample was determined by HPLC
analysis. The results are shown in Table 2.
Table 2 Time Cumulative Drug Release Cumulative Drug Release (days) ( g) (% of initial 80 g) 1 1.70 1.84 2.18 2.17 3 28.6 32 36.67 37.65 8 73 76.6 93.59 90.12 11* 65 69.4 83.33 81.65 * Drug may be degrading in the dissolution medium.
Example 6: Implant composition containing 200 pg of a prostaglandin.
Two 3 l-sized cylindrical pellets each containing 200 g of (5Z)-(9R,11 R,15R)-9-chloro-1 5-cyclohexyl-1 1,1 5-dihydroxy-3-oxa-16,17,18,19,20-pentanor-5-prostenoic acid isopropyl ester were prepared by combining the prostaglandin analogue with the necessary amount of the product Compritol 888 ATO
(Gattefossa) in a scintillation vial, melting the lipophilic compounds by heating in a water bath, mixing by swirling, and then cooling the mixed, melted formulations in cylindrical molds. According to the manufacturer, Compritol 888 ATO is composed of mono-, di- and triglycerides of behenic acid, with the diester fraction being predominant. Compritol 888 ATO is synthesized by esterification of glycerol by behenic acid.
The release of the prostaglandin analogue from the pellets was measured as follows: after weighing, the pellets were placed in scintillation vials with 20 ml of PBS. The vials were stored in a 37 C oven. At each time point, the vial was gently inverted a few times (about 5 times), then 300 l of the dissolution sample was removed from the vial and the vial returned to the oven. The amount of prostaglandin analogue contained in the sample was determined by HPLC
analysis. The results are shown in Table 3.
Table 3 Time Cumulative Drug Release Cumulative % Drug Release (days) ( g) (% of initial 80 g) 1 12.18 11.38 5.37 4.78 3 3.32 3.02 1.46 1.27 8 12.1 14.04 5.33 5.90 11 25.6 31 11.28 13.03 15 52.6 66.4 23.17 27.90 22 54.6 102.4 24.05 43.03 30 88.8 107.4 39.12 45.13 The invention has been described by reference to certain preferred embodiments; however, it should be understood that it may be embodied in other specific forms or variations thereof without departing from its spirit or essential characteristics. The embodiments described above are therefore considered to be illustrative in all respects and not restrictive, the scope of the invention being indicated by the appended claims rather than by the foregoing description.
Claims (23)
1. An intraocular implant composition suitable for implanting in a site selected from the group consisting of the punctum, lacrimal canaliculus, anterior segment, posterior segment, sub-Tenon's space, suprachoroidal space, and subconjunctival space comprising a lipophilic compound having a molecular weight of 150 - 4000 and a pharmaceutically effective amount of a drug, but lacking a polymeric ingredient and an organic solvent that is miscible with or dispersible in water, wherein the composition is solid or semi-solid at temperatures <= 37°C and the lipophilic compound is of the formula wherein R1 is -H, -OH, -COOH, -C n H2n+1-2m, -COOC n H2n+1-2m, -COO(CH2CH2O)n CH2CH2OH, -CH2R3, or R2, R3 and R4 are independently -H, -OH, -COOH, -C n 2n+1-2m, -OOCC n H2n+1-2m, -COOC n H2n+1-2m, -COO(CH2CH2O)n CH2CH2OH, -C n H2n+1-2m COO(CH2CH2O),CH2CH2OH, -OOCC n H2n+1-2m COOC n'H2n'+1-2m', -COO-Na+, -COO-K+, -SO3H, -SO3-Na+, -S03-K+, -NH2, -CI, or n, n' and n" are independently 0 - 50; and m and m' are independently 0 - 10, wherein the composition comprises at least 30% (wt.) of the lipophilic compound of formula (I).
2. The intraocular implant composition of claim 1 wherein the molecular weight of the lipophilic compound of formula (I) is <= 2000
3 The intraocular implant composition of claim 2 wherein the molecular weight of the lipophilic compound of formula (I) is <= 1000.
4. The intraocular implant composition of claim 1 wherein the composition comprises a mixture of two or more lipophilic compounds of formula (I).
5. The intraocular implant composition of claim 1 wherein the lipophilic compound of formula (I) has a melting point >= 34°C.
6. The intraocular implant composition of claim 4 wherein at least one lipophilic compound of formula (t) has a melting point < 34°C but the mixture has a melting point >= 34°C.
7. The intraocular implant composition of claim 1 wherein R1 is -CnH2n+1-2m, -COOCnH2n+1-2m.
-COO(CH2CH2O)nCH2CH2OH, -CH2R3, or R2, R3 and R4 are independently -H, -OH, -COOH, -CnH2n+1-2m, -COOCnH2n+1-2m, -COOCnH2n+1-2m, -COO(CH2CH2O)nCH2CH2OH, -CnH2n+1-2m COO(CH2CH2O)nCH2CH2OH, or -OOCCnH2n+1-2m COOCnH2n'+1-2m n, n' and n" are independently 0 - 40; and m and m' are independently 0 - 5.
-COO(CH2CH2O)nCH2CH2OH, -CH2R3, or R2, R3 and R4 are independently -H, -OH, -COOH, -CnH2n+1-2m, -COOCnH2n+1-2m, -COOCnH2n+1-2m, -COO(CH2CH2O)nCH2CH2OH, -CnH2n+1-2m COO(CH2CH2O)nCH2CH2OH, or -OOCCnH2n+1-2m COOCnH2n'+1-2m n, n' and n" are independently 0 - 40; and m and m' are independently 0 - 5.
8. The intraocular implant composition of claim 7 wherein R1 is R2, R3 and R4 are independently -H, -OH, -COOH, -CnH2n+1-2m, or -OOCCnH2n+1-2m;
n, n' and n" are independently 0 - 30: and m and m' are independently 0 - 3.
n, n' and n" are independently 0 - 30: and m and m' are independently 0 - 3.
9. The intraocular implant composition of claim 1 wherein the lipophilic compound of formula (1) is selected,from the group consisting of diethylene glycol monostearate, propylene glycol monostearate, glyceryl monostearate, glyceryl monolinoleate, glyceryl monooleate, glyceryl monopalmitate, and mixtures thereof.
10. The intraocular implant composition of claim 1 wherein the lipophilic compound of formula (I) is selected from the group consisting of: glyceryl monolaurate, glyceryl dilaurate, glyceryl monomyristate, glyceryl dimyristate, glyceryl monopalmitate, glyceryl dipalmitate, glyceryl monostearate, glyceryl distearate, glyceryl monooleate, glyceryl dioleate, glyceryl monolinoleate, glyceryi dilinoleate, glyceryl monoarachidate, glyceryl diarachidate, glyceryl monobehenate, and glyceryl dibehenate.
11. The intraocular implant composition of claim 1 wherein the composition comprises at least 50%
(wt.) of the lipophilic compound of formula (I).
(wt.) of the lipophilic compound of formula (I).
12. The intraocular implant composition of claim 1 wherein the drug is selected from the group consisting of anti-glaucoma agents, anti-infective agents, non-steroidal and steroidal anti-inflammatory agents, growth factors, immunosuppressant agents, neuroprotectant agents, angiogenesis-inhibiting agents and anti-allergy agents.
13. The intraocular implant composition of claim 1 wherein the composition further comprises one or more excipients selected from the group consisting of surfactants, preservatives, and stabilizers.
14. The intraocular implant composition of claim 13 wherein the composition comprises a surfactant selected from the group consisting of tyloxapol, polysorbate 20, polysorbate 60, and polysorbate 80.
15. The intraocular implant composition of claim 13 wherein the composition comprises a preservative selected from the group consisting of quaternary ammonium preservatives.
16. The intraocular implant composition of claim 13 wherein the composition comprises a stabilizer selected from the group consisting of chelating agents, and antioxidants.
17. The intraocular implant composition of claim 1 wherein the composition is fashioned into a cylindrical, conical and spherical shape.
18. A use of an intraocular implant composition for treating an ophthalmic disease or disorder, comprising the steps of the intraocular implant composition comprising a lipophilic compound having a molecular weight of 150 - 4000 and a pharmaceutically effective amount of an ophthalmically acceptable drug, but lacking a polymeric ingredient and an organic solvent that is miscible with or dispersible in water, wherein the composition is solid or semi-solid at temperatures <= 37 °C and the lipophilic compound is of the formula wherein R1 is -H, -OH, -COOH, -C n H2n+1-2m, -COOC n H2n+1-2m, -COO(CH2CH2O)n CH2CH2OH, -CH2R3, or R2, R3 and R4 are independently -H, -OH, -COOH, -C n H2n+1-2m, -OOCC n H2n+1-2m, -COOC n H2n+1-2m, -COO(CH2CH2O)n CH2CH2OH, -C n H2n+1-2m COO(CH2CH2O)n CH2CH2OH, -OOCC n H2n+1-2m COOC n'H2n'+1-2m', -COO-Na+, -COO-K+, -SO3H, -SO3-Na+, - SO3-K+, -NH2, -Cl, , or Cl-;
n, n' and n" are independently 0 - 50; and m and m' are independently 0 - 10, wherein the composition comprises at least 30% (wt.) of the lipophilic compound of formula (I).
n, n' and n" are independently 0 - 50; and m and m' are independently 0 - 10, wherein the composition comprises at least 30% (wt.) of the lipophilic compound of formula (I).
19. A use of an opthalmically acceptable drug in the manufacture of a medicament for treating an ophthalmic disease or disorder, wherein the medicament is an intraocular plant composition comprising a lipophilic compound having a molecular weight of 150 - 4000 and a pharmaceutically effective amount of the ophthalmically acceptable drug, but lacking a polymeric ingredient and an organic solvent that is miscible with or dispersible in water, wherein the composition is solid or semi-solid at temperatures <= 37 °C and the lipophilic compound is of the formula wherein R1 is -H, -OH, -COOH, -C n H2n+1-2m, -COOC n H2n+1-2m, -COO(CH2CH2O)n CH2CH2OH, -CH2R3, or R2, R3 and R4 are independently -H, -OH, -COOH, -C n H2n+1-2m, -OOCC n H2n+1-2m, -COOC n H2n+1-2m, -COO(CH2CH2O)n CH2CH2OH, -C n H2n+1-2m COO(CH2CH2O)n CH2CH2OH, -OOCC n H2n+1-2m COOC n-H2n'+1-2m', -COO-Na+, -COO-K+, -SO3H, -SO3 Na+, - SO3 -K+, -NH2, -Cl, , or Cl-;
n, n' and n" are independently 0 - 50; and m and m' are independently 0 - 10, wherein the composition comprises at least 30% (wt.) of the lipophilic compound of formula (I).
n, n' and n" are independently 0 - 50; and m and m' are independently 0 - 10, wherein the composition comprises at least 30% (wt.) of the lipophilic compound of formula (I).
20. The use of claims 18 or 19, wherein the composition is in a form for implantation into the eye in a site selected from the group consisting of the punctum, lacrimal canaliculus, anterior segment, posterior segment, sub-Tenon's space, suprachoroidal space, and subconjunctival space.
21. The use of any one of claims 18 to 20 wherein the composition is warmed to a temperature above room temperature before delivery through a cannula.
22. The use of any one of claims 18 to 20 wherein the composition is in the form of a solid or semi-solid for delivery to the eye.
23. The use of any one of claims 18 to 20 wherein the intraocular implant composition is suspended in a liquid carrier for implantation in the eye by delivery through a cannula.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39584002P | 2002-07-15 | 2002-07-15 | |
| US60/395,840 | 2002-07-15 | ||
| PCT/US2003/020707 WO2004006890A1 (en) | 2002-07-15 | 2003-06-30 | Non-polymeric lipophilic pharmaceutical implant compositions for intraocular use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2491313A1 CA2491313A1 (en) | 2004-01-22 |
| CA2491313C true CA2491313C (en) | 2011-05-24 |
Family
ID=30115932
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2491313A Expired - Fee Related CA2491313C (en) | 2002-07-15 | 2003-06-30 | Non-polymeric lipophilic pharmaceutical implant compositions for intraocular use |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US7678827B2 (en) |
| EP (1) | EP1521573B1 (en) |
| JP (1) | JP4463681B2 (en) |
| KR (1) | KR101003518B1 (en) |
| CN (1) | CN100355455C (en) |
| AT (1) | ATE382330T1 (en) |
| AU (1) | AU2003248777B2 (en) |
| BR (1) | BR0312635A (en) |
| CA (1) | CA2491313C (en) |
| CY (1) | CY1107166T1 (en) |
| DE (1) | DE60318446T2 (en) |
| DK (1) | DK1521573T3 (en) |
| ES (1) | ES2295647T3 (en) |
| MX (1) | MXPA05000632A (en) |
| PL (1) | PL206594B1 (en) |
| PT (1) | PT1521573E (en) |
| WO (1) | WO2004006890A1 (en) |
| ZA (2) | ZA200410096B (en) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6955661B1 (en) * | 1999-01-25 | 2005-10-18 | Atrium Medical Corporation | Expandable fluoropolymer device for delivery of therapeutic agents and method of making |
| US7947015B2 (en) * | 1999-01-25 | 2011-05-24 | Atrium Medical Corporation | Application of a therapeutic substance to a tissue location using an expandable medical device |
| US7431710B2 (en) | 2002-04-08 | 2008-10-07 | Glaukos Corporation | Ocular implants with anchors and methods thereof |
| US20070184089A1 (en) * | 2002-07-15 | 2007-08-09 | Alcon, Inc. | Non-Polymeric Lipophilic Pharmaceutical Implant Compositions for Intraocular Use |
| PT1521573E (en) * | 2002-07-15 | 2008-02-08 | Alcon Inc | Non-polymeric lipophilic pharmaceutical implant compositions for intraocular use |
| US20050244463A1 (en) | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Sustained release intraocular implants and methods for treating ocular vasculopathies |
| JP5097883B2 (en) * | 2004-09-02 | 2012-12-12 | 株式会社 神崎高級工機製作所 | Hydraulic drive vehicle |
| US9000040B2 (en) | 2004-09-28 | 2015-04-07 | Atrium Medical Corporation | Cross-linked fatty acid-based biomaterials |
| US9012506B2 (en) | 2004-09-28 | 2015-04-21 | Atrium Medical Corporation | Cross-linked fatty acid-based biomaterials |
| EP1811933B1 (en) | 2004-09-28 | 2016-03-23 | Atrium Medical Corporation | Barrier layer |
| EP1928407B1 (en) * | 2005-09-21 | 2009-03-18 | Aston University | Chronotherapeutic ocular delivery system comprising a combination of prostaglandin and a beta-blocker for treating primary glaucoma |
| US9427423B2 (en) | 2009-03-10 | 2016-08-30 | Atrium Medical Corporation | Fatty-acid based particles |
| US9278161B2 (en) | 2005-09-28 | 2016-03-08 | Atrium Medical Corporation | Tissue-separating fatty acid adhesion barrier |
| US9474645B2 (en) * | 2006-06-21 | 2016-10-25 | Johnson & Johnson Vision Care, Inc. | Punctal plugs for the delivery of active agents |
| US20080045911A1 (en) * | 2006-06-21 | 2008-02-21 | Borgia Maureen J | Punctal plugs for the delivery of active agents |
| US9173773B2 (en) * | 2006-06-21 | 2015-11-03 | Johnson & Johnson Vision Care, Inc. | Punctal plugs for the delivery of active agents |
| UY30883A1 (en) | 2007-01-31 | 2008-05-31 | Alcon Res | PUNCTURAL PLUGS AND METHODS OF RELEASE OF THERAPEUTIC AGENTS |
| MX2010002616A (en) * | 2007-09-07 | 2010-08-04 | Qlt Plug Delivery Inc | Drug cores for sustained release of therapeutic agents. |
| TWI498136B (en) * | 2007-10-09 | 2015-09-01 | Alcon Res Ltd | An injection device for delivering a rate and temperature-dependent substance into the eye and method of preparing the same |
| TWI451862B (en) * | 2007-10-09 | 2014-09-11 | Alcon Res Ltd | Thermal coefficient driven drug pellet size for ophthalmic injection |
| JP2010104632A (en) | 2008-10-31 | 2010-05-13 | Hoya Corp | Ophthalmic composition having gelling ability |
| US9095506B2 (en) | 2008-11-17 | 2015-08-04 | Allergan, Inc. | Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof |
| US8632511B2 (en) * | 2009-05-06 | 2014-01-21 | Alcon Research, Ltd. | Multiple thermal sensors in a multiple processor environment for temperature control in a drug delivery device |
| US10206813B2 (en) | 2009-05-18 | 2019-02-19 | Dose Medical Corporation | Implants with controlled drug delivery features and methods of using same |
| US20110038910A1 (en) | 2009-08-11 | 2011-02-17 | Atrium Medical Corporation | Anti-infective antimicrobial-containing biomaterials |
| PL2498783T3 (en) | 2009-11-09 | 2019-04-30 | Allergan Inc | Compositions and methods for stimulating hair growth |
| US8177747B2 (en) * | 2009-12-22 | 2012-05-15 | Alcon Research, Ltd. | Method and apparatus for drug delivery |
| CA2767068C (en) * | 2009-12-22 | 2016-09-27 | Ucb Pharma Gmbh | Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine |
| EP2593141B1 (en) | 2010-07-16 | 2018-07-04 | Atrium Medical Corporation | Composition and methods for altering the rate of hydrolysis of cured oil-based materials |
| DE102011016277B4 (en) * | 2011-04-06 | 2013-02-21 | Heraeus Medical Gmbh | Plastic deformable, biodegradable hemostyptic and method of molding such |
| US9867880B2 (en) | 2012-06-13 | 2018-01-16 | Atrium Medical Corporation | Cured oil-hydrogel biomaterial compositions for controlled drug delivery |
| US20140234389A1 (en) | 2013-02-15 | 2014-08-21 | Allergan, Inc. | Sustained drug delivery implant |
| WO2015046281A1 (en) * | 2013-09-26 | 2015-04-02 | 参天製薬株式会社 | Aqueous composition containing stabilized 2-amino-3-(4-bromobenzoyl)phenylacetic acid |
| US20150342875A1 (en) | 2014-05-29 | 2015-12-03 | Dose Medical Corporation | Implants with controlled drug delivery features and methods of using same |
| WO2017040853A1 (en) | 2015-09-02 | 2017-03-09 | Glaukos Corporation | Drug delivery implants with bi-directional delivery capacity |
| US11564833B2 (en) | 2015-09-25 | 2023-01-31 | Glaukos Corporation | Punctal implants with controlled drug delivery features and methods of using same |
| US11318043B2 (en) | 2016-04-20 | 2022-05-03 | Dose Medical Corporation | Bioresorbable ocular drug delivery device |
| ES2907847T3 (en) * | 2016-09-30 | 2022-04-26 | Mati Therapeutics Inc | Ophthalmic drug sustained release formulation and its uses |
| JP7128846B2 (en) | 2017-06-13 | 2022-08-31 | アルコン インコーポレイティド | intraocular lens composition |
| RU2675691C1 (en) * | 2017-09-14 | 2018-12-21 | Федеральное Государственное бюджетное образовательное учреждение высшего образования Дагестанский государственный медицинский университет Министерства здравоохранения Российской Федерации | Method of long-term perfusion of subtenon space with medicines |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4014335A (en) * | 1975-04-21 | 1977-03-29 | Alza Corporation | Ocular drug delivery device |
| JPS6042766B2 (en) * | 1978-12-09 | 1985-09-25 | 日本化薬株式会社 | Base |
| US4797288A (en) * | 1984-10-05 | 1989-01-10 | Warner-Lambert Company | Novel drug delivery system |
| GB8524421D0 (en) * | 1985-10-03 | 1985-11-06 | Boots Co Plc | Therapeutic agents |
| US4997652A (en) * | 1987-12-22 | 1991-03-05 | Visionex | Biodegradable ocular implants |
| US4853224A (en) * | 1987-12-22 | 1989-08-01 | Visionex | Biodegradable ocular implants |
| JP2893191B2 (en) * | 1988-11-08 | 1999-05-17 | 武田薬品工業株式会社 | Controlled release matrix agent |
| US5015474A (en) * | 1988-11-22 | 1991-05-14 | Parnell Pharmaceuticals, Inc. | Composition for imparting moisture to a substrate |
| ATE138071T1 (en) * | 1989-02-17 | 1996-06-15 | Liposome Co Inc | LIPID AIDS FOR ADMINISTRATION THROUGH THE NOSE AND TOPICAL APPLICATION |
| US5164188A (en) * | 1989-11-22 | 1992-11-17 | Visionex, Inc. | Biodegradable ocular implants |
| US5660851A (en) * | 1989-12-26 | 1997-08-26 | Yissum Research Development Company Of The Hebrew Univ. Of Jerusalem | Ocular inserts |
| DE69129696T2 (en) | 1990-04-27 | 1999-02-25 | Allergan Inc | POLYMER DRUG DELIVERY SYSTEM |
| IE65045B1 (en) | 1990-04-28 | 1995-10-04 | Takeda Chemical Industries Ltd | Granulated preparations and method of producing the same |
| US5378475A (en) * | 1991-02-21 | 1995-01-03 | University Of Kentucky Research Foundation | Sustained release drug delivery devices |
| WO1992020334A1 (en) * | 1991-05-13 | 1992-11-26 | The Boots Company Plc | Pharmaceutical composition comprising ibuprofen salt |
| US5629019A (en) * | 1992-02-27 | 1997-05-13 | Alza Corporation | Formulations with hydrophobic permeation enhancers |
| US5178635A (en) * | 1992-05-04 | 1993-01-12 | Allergan, Inc. | Method for determining amount of medication in an implantable device |
| WO1994005257A1 (en) | 1992-09-08 | 1994-03-17 | Allergan, Inc. | Sustained release of ophthalmic drugs from a soluble polymer drug delivery vehicle |
| WO1995003009A1 (en) * | 1993-07-22 | 1995-02-02 | Oculex Pharmaceuticals, Inc. | Method of treatment of macular degeneration |
| US5433951A (en) * | 1993-10-13 | 1995-07-18 | Bristol-Myers Squibb Company | Sustained release formulation containing captopril and method |
| US5443505A (en) | 1993-11-15 | 1995-08-22 | Oculex Pharmaceuticals, Inc. | Biocompatible ocular implants |
| US5773021A (en) | 1994-03-14 | 1998-06-30 | Vetoquinol S.A. | Bioadhesive ophthalmic insert |
| CA2119109C (en) | 1994-03-15 | 2002-11-12 | Florian Gurtler | Bioadhesive ophthalmic insert |
| PT754032E (en) | 1994-04-08 | 2002-05-31 | Atrix Lab Inc | LIQUID COMPOSITIONS FOR DIFFUSE |
| US6190691B1 (en) | 1994-04-12 | 2001-02-20 | Adolor Corporation | Methods for treating inflammatory conditions |
| US5466233A (en) * | 1994-04-25 | 1995-11-14 | Escalon Ophthalmics, Inc. | Tack for intraocular drug delivery and method for inserting and removing same |
| AUPM897594A0 (en) | 1994-10-25 | 1994-11-17 | Daratech Pty Ltd | Controlled release container |
| ATE232089T1 (en) | 1994-11-10 | 2003-02-15 | Univ Kentucky Res Found | CONTROLLED RELEASE IMPLANTABLE REFILLABLE DEVICE FOR ADMINISTERING DRUGS IMMEDIATELY TO AN INTERNAL PART OF THE BODY |
| US5725493A (en) | 1994-12-12 | 1998-03-10 | Avery; Robert Logan | Intravitreal medicine delivery |
| US5718922A (en) * | 1995-05-31 | 1998-02-17 | Schepens Eye Research Institute, Inc. | Intravitreal microsphere drug delivery and method of preparation |
| US5869079A (en) | 1995-06-02 | 1999-02-09 | Oculex Pharmaceuticals, Inc. | Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents |
| US5773019A (en) | 1995-09-27 | 1998-06-30 | The University Of Kentucky Research Foundation | Implantable controlled release device to deliver drugs directly to an internal portion of the body |
| US5736152A (en) | 1995-10-27 | 1998-04-07 | Atrix Laboratories, Inc. | Non-polymeric sustained release delivery system |
| AU5347696A (en) | 1995-11-20 | 1997-06-11 | Kiyoshi Kita | External preparation containing vitamin d or vitamin k |
| US5797898A (en) | 1996-07-02 | 1998-08-25 | Massachusetts Institute Of Technology | Microchip drug delivery devices |
| CA2283780A1 (en) * | 1997-03-12 | 1998-09-17 | Abbott Laboratories | Lipophilic binary systems for the administration of lipophilic compounds |
| US6143276A (en) | 1997-03-21 | 2000-11-07 | Imarx Pharmaceutical Corp. | Methods for delivering bioactive agents to regions of elevated temperatures |
| US6120751A (en) | 1997-03-21 | 2000-09-19 | Imarx Pharmaceutical Corp. | Charged lipids and uses for the same |
| JP2001513369A (en) | 1997-08-11 | 2001-09-04 | アラーガン・セイルズ・インコーポレイテッド | Sterile bioerodible implant devices and methods with improved biocompatibility |
| IL121647A (en) * | 1997-08-28 | 2001-07-24 | Pharmateam Dev Ltd | Pharmaceutical compositions for the treatment of ocular inflammation comprising dexamethasone palmitate |
| US5902598A (en) | 1997-08-28 | 1999-05-11 | Control Delivery Systems, Inc. | Sustained release drug delivery devices |
| US6099853A (en) * | 1997-09-04 | 2000-08-08 | Protein Express | Vaginal suppository vaccine for urogenital infections |
| US5891476A (en) * | 1997-12-22 | 1999-04-06 | Reo; Joe P. | Tastemasked pharmaceutical system |
| DE19804310A1 (en) * | 1998-02-04 | 1999-08-05 | Aventis Res & Tech Gmbh & Co | Spiro compounds and their use |
| DE10030378A1 (en) | 2000-06-21 | 2002-03-14 | Audit Inst For Medical Service | New pharmaceutical composition for topical application of water-insoluble and / or poorly water-soluble active ingredients |
| WO2001097832A1 (en) | 2000-06-21 | 2001-12-27 | Audit Institute For Medical Services And Quality Assurance Gmbh | Pharmaceutical preparations containing cyclosporines and neutral oils |
| AR038628A1 (en) | 2002-03-04 | 2005-01-19 | Novartis Ag | OPHTHALM COMPOSITION |
| PT1521573E (en) * | 2002-07-15 | 2008-02-08 | Alcon Inc | Non-polymeric lipophilic pharmaceutical implant compositions for intraocular use |
| US7297709B2 (en) | 2003-05-22 | 2007-11-20 | Abbott Laboratories | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors |
-
2003
- 2003-06-30 PT PT03764334T patent/PT1521573E/en unknown
- 2003-06-30 CN CNB038167913A patent/CN100355455C/en not_active Expired - Fee Related
- 2003-06-30 ES ES03764334T patent/ES2295647T3/en not_active Expired - Lifetime
- 2003-06-30 BR BR0312635-8A patent/BR0312635A/en not_active IP Right Cessation
- 2003-06-30 MX MXPA05000632A patent/MXPA05000632A/en active IP Right Grant
- 2003-06-30 KR KR1020057000488A patent/KR101003518B1/en not_active IP Right Cessation
- 2003-06-30 CA CA2491313A patent/CA2491313C/en not_active Expired - Fee Related
- 2003-06-30 WO PCT/US2003/020707 patent/WO2004006890A1/en active IP Right Grant
- 2003-06-30 PL PL374743A patent/PL206594B1/en not_active IP Right Cessation
- 2003-06-30 AT AT03764334T patent/ATE382330T1/en active
- 2003-06-30 DK DK03764334T patent/DK1521573T3/en active
- 2003-06-30 DE DE60318446T patent/DE60318446T2/en not_active Expired - Lifetime
- 2003-06-30 JP JP2004521511A patent/JP4463681B2/en not_active Expired - Fee Related
- 2003-06-30 EP EP03764334A patent/EP1521573B1/en not_active Expired - Lifetime
- 2003-06-30 US US10/610,435 patent/US7678827B2/en not_active Expired - Fee Related
- 2003-06-30 AU AU2003248777A patent/AU2003248777B2/en not_active Ceased
-
2004
- 2004-12-14 ZA ZA200410096A patent/ZA200410096B/en unknown
- 2004-12-14 ZA ZA200410095A patent/ZA200410095B/en unknown
-
2008
- 2008-01-31 CY CY20081100111T patent/CY1107166T1/en unknown
- 2008-06-03 US US12/132,003 patent/US8178576B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1668277A (en) | 2005-09-14 |
| CA2491313A1 (en) | 2004-01-22 |
| PL206594B1 (en) | 2010-08-31 |
| PT1521573E (en) | 2008-02-08 |
| JP2006500328A (en) | 2006-01-05 |
| EP1521573B1 (en) | 2008-01-02 |
| CY1107166T1 (en) | 2012-10-24 |
| ZA200410096B (en) | 2006-07-26 |
| MXPA05000632A (en) | 2005-03-31 |
| KR20050023409A (en) | 2005-03-09 |
| CN100355455C (en) | 2007-12-19 |
| KR101003518B1 (en) | 2010-12-30 |
| DE60318446T2 (en) | 2008-05-21 |
| US7678827B2 (en) | 2010-03-16 |
| DK1521573T3 (en) | 2008-03-25 |
| AU2003248777A1 (en) | 2004-02-02 |
| ZA200410095B (en) | 2006-07-26 |
| ATE382330T1 (en) | 2008-01-15 |
| US20080241224A1 (en) | 2008-10-02 |
| ES2295647T3 (en) | 2008-04-16 |
| AU2003248777B2 (en) | 2008-02-14 |
| DE60318446D1 (en) | 2008-02-14 |
| EP1521573A1 (en) | 2005-04-13 |
| PL374743A1 (en) | 2005-10-31 |
| WO2004006890A1 (en) | 2004-01-22 |
| BR0312635A (en) | 2005-04-19 |
| JP4463681B2 (en) | 2010-05-19 |
| US20040013704A1 (en) | 2004-01-22 |
| US8178576B2 (en) | 2012-05-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2491313C (en) | Non-polymeric lipophilic pharmaceutical implant compositions for intraocular use | |
| JP6371438B2 (en) | Nonlinear multiblock copolymer drug conjugates for delivery of active agents | |
| JP5826872B2 (en) | Method for producing cyclic lipid implants for intraocular use | |
| US20070184089A1 (en) | Non-Polymeric Lipophilic Pharmaceutical Implant Compositions for Intraocular Use | |
| JPH02702A (en) | Biodegradable eye implant | |
| BRPI0613401B1 (en) | OPHTHALMIC COMPOSITION UNDERSTANDING GLYCOCORTICOID DERIVATIVES THAT SELECTIVELY PENETRATE IN THE TISSUES OF THE BACK SEGMENT | |
| TW200538163A (en) | Retinoid-containing sustained release intraocular drug delivery systems and related methods | |
| WO2009143288A1 (en) | Biodegradable sustained-release polymeric microparticulates comprising a hydrophobic drug and determined for ophthalmic use | |
| Deshpande et al. | Bioerodible polymers for ocular drug delivery | |
| CA2704111C (en) | Hypercompressed particles for controlled release of ophthalmic medications | |
| Mezei et al. | Liposomes and nanoparticles as ocular drug delivery systems | |
| Boddu et al. | Novel nanoparticulate gel formulations of steroids for the treatment of macular edema | |
| JP6250005B2 (en) | Controlled release formulation | |
| WO2012054498A1 (en) | Polymeric microparticles | |
| US20200297651A1 (en) | PPARa AGONIST COMPOSITIONS AND METHODS OF USE | |
| Rupenthal et al. | Ocular drug delivery | |
| CA2176145C (en) | Biocompatible ocular implants | |
| Dwivedi et al. | Review on ocular inserts | |
| Bqqmjdbujpot | Esvh Efmjwfsz Tztufnt jo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20180703 |